Kimberly-Clark (KMB) Stock Forecast & Price Target

Kimberly-Clark is a leading manufacturer of personal care and consumer tissue products, generating over half its sales from North America. While the company's 1Q26 top-line momentum is on track and its costs are hedged, there is potential risk to its 2027 outlook due to elevated oil costs, which make up approximately 25% of its total COGS basket. The company's upcoming deal with Kenvue has the potential for significant cost synergies, but may initially be dilutive to EPS. Despite transformation efforts, uncertainty surrounding input costs and consumer spending has led to a lowered target price of $114, using a ~15.0x PE multiple.

Kimberly-Clark is facing softening momentum in the North American market in the second quarter of 2026, which will negatively impact its organic sales growth. However, the company's efforts to ramp up merchandising, innovation, and cost management should help improve its performance in the second half of the year. The recent pullback in oil prices may also provide some relief, but the KVUE acquisition's full impact will not be felt until 2028. Overall, while there may be potential for upside from the deal in the future, the short-term outlook is muted.